The digital therapeutics (DTx) market has witnessed over 400 collaborations. Solution providers established four types of partnership ecosystems to foster development, aid market entry, and facilitate the integration of DTx.
Digital therapeutics (DTx) market segment is still developing, striving to deliver clinically proven and medically approved software solutions in various disease areas and to integrate them in the traditional healthcare.
Strategic partnerships play a key role in facilitating the acceptance, integration and growth of DTx solutions as well as increasing the awareness about their potential benefits.
According to Allis, the number of closed partnerships with DTx solution providers has surpassed 400 to date, and this trend has seen a consistent increase from 2014 to 2020, with a rise from a single partnership deal to 90 partnership deals.
Despite facing bankruptcies and layoffs within some companies developing DTx solutions, the first half of 2023 has seen also seen considerable number of partnerships being forged with DTx solution providers, totalling around 40.
This demonstrates a growing interest among the healthcare stakeholders, including health plans, pharma, healthcare and research organizations among others, for DTx collaborations.
Recently NuvoAir and Marpai collaborated to offer NuvoAir’s respiratory and heart failure virtual care services to the members of self-funded employer health plans.
Click Therapeutics-Boehringer Ingelheim for schizophrenia, Dawn Health-Novartis for chronic conditions, Welldoc-Astellas Pharma for cardiometabolic conditions, and Biofourmis-Chugai for endometriosis are just a few examples of DTx-pharma collaborations happened in the last six months.
Some DTx providers have also succeeded closing partnerships with hospitals, such as Ampersand Health and Barts Health, Propeller Health and UC Davis Health and Rocket VR and Massachusetts General Hospital.
As the list of partners for DTx solution providers continues to grow, four types of partnership ecosystems also started to be formed in the market segment.
Over the years, the digital therapeutics (DTx) industry has witnessed a steady rise in partnership deals and forged numerous collaborations with various healthcare stakeholders. As a result, DTx players are now establishing their own ecosystems, consisting of four key types: pharma industry, commercial, research, and service expansion. These ecosystems collectively contribute to the development, integration, and acceptance of the DTx solutions in traditional healthcare delivery, and eventually boost the growth of DTx business.